Perrigo

SK Capital to acquire Perrigo’s Active Pharmaceutical Ingredients Business

Tuesday, August 15, 2017

SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, has signed a definitive agreement to acquire Perrigo API, Perrigo’s active pharmaceutical ingredients (API) business. As part of the transaction, the parties have agreed to enter into a long-term supply agreement for Perrigo API to supply multiple existing commercial and pipeline APIs to Perrigo. The transaction is expected to close during Q4 2017, before which a new trade name will be selected and announced for the Business.

[Read More]

Bristol-Myers Squibb appoints three new independent directors

Tuesday, February 21, 2017

Bristol-Myers Squibb has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels to its board of directors, effective immediately. In connection with these appointments, the board will temporarily expand to 14 directors until the 2017 Annual Meeting, to be held on May 2, 2017. Only 11 directors will stand for election at the meeting. Bristol-Myers Squibb also announced that it has entered into an accelerated share repurchase (ASR) program to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock.

[Read More]

Valeant names Joseph C. Papa chairman, CEO

Tuesday, April 26, 2016

Valeant Pharmaceuticals International has named Joseph C. Papa to become Valeant’s chairman and chief executive officer. Papa is expected to join Valeant by early May. Papa will join Valeant from Perrigo company, a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as chairman and chief executive officer. Papa, who will also join Valeant’s board of directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a director until Papa arrives at Valeant.

[Read More]

Mylan cleared by FTC to acquire Perrigo

Thursday, November 5, 2015

Mylan has announced the U.S. Federal Trade Commission (FTC) has cleared the company’s proposed transaction to acquire Perrigo subject to Mylan’s divestiture of certain products following the consummation of the offer. The FTC clearance represents the final regulatory clearance needed by Mylan to close its acquisition of Perrigo and represents the last remaining condition that needs to be satisfied for the successful completion of the offer other than the acceptance condition.

[Read More]

Perrigo cuts 800 jobs

Friday, October 23, 2015

Perrigo has announced a $2 billion share repurchase plan. The plan includes $500 million in repurchases that will be completed by the end of 2015, and an additional $1.5 billion in repurchases that the company expects to complete over the subsequent 24 to 36 months, which are expected to be funded through available liquidity. Perrigo also will reduce its workforce by about 800 employees, or 6% of its current global headcount.

[Read More]

Teva rebuts Mylan chairman’s letter

Wednesday, June 10, 2015

Erez Vigodman, Teva’s president and CEO, has responded to the June 1 letter by Mylan’s executive chairman Robert J. Coury. Vigodman addresses Courey’s accusations about Teva’s hostile takeover of Mylan and the lack of information available to stakeholders.

[Read More]